Repligen, ImClone In Patent Dispute Over Erbitux Cell Lines
This article was originally published in The Pink Sheet Daily
Executive Summary
Repligen is seeking damages from ImClone for allegedly using a cell line covered by a Repligen patent to produce the oncologic. The patent expired in May, but Repligen seeks to hold ImClone liable for product that was manufactured before the patent’s expiration.
You may also be interested in...
Repligen Settles With ImClone On Erbitux Suit
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.
Repligen Settles With ImClone On Erbitux Suit
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.
Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials
Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.